ArticleNature medicine2001
Immune privilege or inflammation? Insights into the Fas ligand enigma.
Article in Nature medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.Human molecular genetics · 2016Pooled it
- Comprehensive narrative review on the analysis of outcomes from cell transplantation clinical trials for discogenic low back pain.North American Spine Society journal · 2023Article
- An in-depth analysis of the immunomodulatory mechanisms of intervertebral disc degeneration.JOR spine · 2022Review
- Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors.Frontiers in oncology · 2019Article
- [Association of FasL-844T/C gene polymorphism with FasL expression in the nucleus pulposus of degenerative lumbar intervertebral discs].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Persistent degenerative changes in the intervertebral disc after burst fracture in an in vitro model mimicking physiological post-traumatic conditions.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2015Article
- Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway.Stem cell research & therapy · 2013Article
- Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- P2X7 signaling promotes microsphere embolism-triggered microglia activation by maintaining elevation of Fas ligand.Journal of neuroinflammation · 2012Article
- Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.Pathology oncology research : POR · 2012Article
- Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver.Gastroenterology · 2009Article
- Fas ligand expression in lynch syndrome-associated colorectal tumours.Pathology oncology research : POR · 2009Article
- Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells.The Journal of biological chemistry · 2009Article
- Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.British journal of cancer · 2008Article
- Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis.The Journal of biological chemistry · 2008Article
- Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.British journal of cancer · 2007Article
- The effects of FasL on inflammation and tumor survival are dependent on its expression levels.Cancer gene therapy · 2007Article
- Immunosuppressive strategies that are mediated by tumor cells.Annual review of immunology · 2007Review
- Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data.Journal of carcinogenesis · 2006Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.